Cargando…

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavelic, Antun R., Wöber, Christian, Riederer, Franz, Zebenholzer, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819019/
https://www.ncbi.nlm.nih.gov/pubmed/36611935
http://dx.doi.org/10.3390/cells12010143
_version_ 1784865128118747136
author Pavelic, Antun R.
Wöber, Christian
Riederer, Franz
Zebenholzer, Karin
author_facet Pavelic, Antun R.
Wöber, Christian
Riederer, Franz
Zebenholzer, Karin
author_sort Pavelic, Antun R.
collection PubMed
description Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs.
format Online
Article
Text
id pubmed-9819019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98190192023-01-07 Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data Pavelic, Antun R. Wöber, Christian Riederer, Franz Zebenholzer, Karin Cells Review Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs. MDPI 2022-12-29 /pmc/articles/PMC9819019/ /pubmed/36611935 http://dx.doi.org/10.3390/cells12010143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pavelic, Antun R.
Wöber, Christian
Riederer, Franz
Zebenholzer, Karin
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title_full Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title_fullStr Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title_full_unstemmed Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title_short Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
title_sort monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819019/
https://www.ncbi.nlm.nih.gov/pubmed/36611935
http://dx.doi.org/10.3390/cells12010143
work_keys_str_mv AT pavelicantunr monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata
AT woberchristian monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata
AT riedererfranz monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata
AT zebenholzerkarin monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata